Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 10 | 2024 | 234 | 3.210 |
Why?
|
| Critical Illness | 8 | 2023 | 98 | 3.000 |
Why?
|
| Sepsis | 7 | 2020 | 74 | 2.670 |
Why?
|
| Critical Care | 7 | 2024 | 97 | 2.580 |
Why?
|
| Physicians | 3 | 2021 | 105 | 1.770 |
Why?
|
| Family | 4 | 2024 | 88 | 1.570 |
Why?
|
| Staphylococcal Infections | 5 | 2020 | 155 | 1.030 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 42 | 1.030 |
Why?
|
| Hospital Mortality | 3 | 2020 | 130 | 1.010 |
Why?
|
| Anxiety | 3 | 2023 | 143 | 0.980 |
Why?
|
| Neoplasms | 2 | 2020 | 218 | 0.920 |
Why?
|
| Depression | 3 | 2023 | 383 | 0.830 |
Why?
|
| Humans | 24 | 2024 | 23187 | 0.800 |
Why?
|
| Communication | 2 | 2023 | 96 | 0.760 |
Why?
|
| Stress, Psychological | 2 | 2021 | 215 | 0.740 |
Why?
|
| Adult | 13 | 2022 | 6959 | 0.700 |
Why?
|
| Palliative Medicine | 1 | 2021 | 7 | 0.700 |
Why?
|
| Bacteremia | 4 | 2020 | 98 | 0.700 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 71 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 220 | 0.640 |
Why?
|
| Patient Advocacy | 1 | 2019 | 9 | 0.610 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 19 | 0.610 |
Why?
|
| HIV Infections | 2 | 2016 | 439 | 0.600 |
Why?
|
| Tracheostomy | 1 | 2018 | 20 | 0.570 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 21 | 0.570 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 5 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 7 | 0.570 |
Why?
|
| Middle Aged | 13 | 2021 | 7981 | 0.570 |
Why?
|
| Patient Care Team | 1 | 2019 | 110 | 0.560 |
Why?
|
| Chronic Disease | 1 | 2019 | 377 | 0.550 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 3 | 0.500 |
Why?
|
| Aged | 11 | 2021 | 7660 | 0.480 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 7 | 0.480 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 84 | 0.470 |
Why?
|
| Male | 13 | 2021 | 12659 | 0.460 |
Why?
|
| Female | 13 | 2021 | 13142 | 0.450 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 52 | 0.450 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 113 | 0.450 |
Why?
|
| Decision Making | 3 | 2021 | 179 | 0.440 |
Why?
|
| Immune System Diseases | 1 | 2014 | 1 | 0.420 |
Why?
|
| Algorithms | 1 | 2016 | 305 | 0.420 |
Why?
|
| Retrospective Studies | 7 | 2018 | 2993 | 0.320 |
Why?
|
| Pandemics | 2 | 2021 | 207 | 0.310 |
Why?
|
| Cytokines | 3 | 2020 | 192 | 0.300 |
Why?
|
| Cross Infection | 1 | 2011 | 295 | 0.290 |
Why?
|
| Hospitalization | 3 | 2021 | 288 | 0.280 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1037 | 0.250 |
Why?
|
| Prognosis | 2 | 2020 | 730 | 0.240 |
Why?
|
| Chicago | 2 | 2019 | 847 | 0.240 |
Why?
|
| Length of Stay | 2 | 2018 | 298 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2016 | 40 | 0.230 |
Why?
|
| Age Factors | 2 | 2018 | 651 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 279 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 804 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 8 | 0.200 |
Why?
|
| Consensus | 1 | 2023 | 81 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2021 | 1512 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3865 | 0.180 |
Why?
|
| Sleep | 1 | 2024 | 270 | 0.180 |
Why?
|
| Th2 Cells | 2 | 2019 | 14 | 0.180 |
Why?
|
| Morals | 1 | 2021 | 13 | 0.180 |
Why?
|
| Th17 Cells | 2 | 2019 | 23 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 10 | 0.170 |
Why?
|
| United States | 3 | 2021 | 1803 | 0.170 |
Why?
|
| Body Temperature | 1 | 2020 | 39 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 81 | 0.160 |
Why?
|
| Palliative Care | 1 | 2021 | 106 | 0.160 |
Why?
|
| Uncertainty | 1 | 2020 | 10 | 0.160 |
Why?
|
| Logistic Models | 2 | 2018 | 357 | 0.160 |
Why?
|
| ROC Curve | 2 | 2018 | 122 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 17 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 2020 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 36 | 0.150 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 1 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2019 | 46 | 0.140 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 6 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 9 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 16 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2018 | 23 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 106 | 0.140 |
Why?
|
| Flow Cytometry | 1 | 2018 | 100 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 30 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 227 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 269 | 0.130 |
Why?
|
| Quality of Life | 1 | 2021 | 564 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2018 | 369 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 399 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2018 | 485 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 381 | 0.120 |
Why?
|
| APACHE | 1 | 2016 | 22 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2016 | 10 | 0.120 |
Why?
|
| Coinfection | 1 | 2016 | 20 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 13 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2016 | 47 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2016 | 32 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 17 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 1264 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 310 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Antioxidant Response Elements | 1 | 2013 | 1 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 20 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2013 | 83 | 0.100 |
Why?
|
| Georgia | 1 | 2011 | 12 | 0.090 |
Why?
|
| HIV-1 | 1 | 2013 | 203 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 60 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 163 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 57 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 483 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 2943 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2016 | 569 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2016 | 537 | 0.050 |
Why?
|
| Child | 2 | 2016 | 1160 | 0.050 |
Why?
|
| Adolescent | 2 | 2016 | 1884 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 1657 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2020 | 25 | 0.040 |
Why?
|
| Fever | 1 | 2020 | 32 | 0.040 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 3271 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 21 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 89 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 139 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 276 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 363 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 314 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 445 | 0.030 |
Why?
|
| Asthma | 1 | 2019 | 152 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 526 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 226 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 9 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 69 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 66 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 157 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1467 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 429 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 633 | 0.030 |
Why?
|
| Quinones | 1 | 2013 | 1 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2013 | 5 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2013 | 5 | 0.020 |
Why?
|
| Thiocyanates | 1 | 2013 | 4 | 0.020 |
Why?
|
| Claudins | 1 | 2013 | 5 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2013 | 10 | 0.020 |
Why?
|
| Occludin | 1 | 2013 | 8 | 0.020 |
Why?
|
| Glutathione | 1 | 2013 | 19 | 0.020 |
Why?
|
| Rats, Transgenic | 1 | 2013 | 17 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 36 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 87 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 283 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 462 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 622 | 0.020 |
Why?
|